RenovoRx
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2570 W El Camino Real Ste 320, Mountain ...Phone Number
(650) 284-4433Website
www.renovorx.comRevenue
<$5 MillionStock Symbol
RNXTIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About RenovoRx
RenovoRx, Inc. (Nasdaq: RNXT) is a targeted oncology company focused on developing and commercializing innovative local drug-delivery therapies for cancer. The companys FDA-cleared RenovoCath® catheter and patented Trans-Arterial Micro-Perfusion (TAMP) platform are designed to deliver therapeutics directly through the arterial wall to bathe tumors at the disease site, with the goal of improving efficacy while reducing systemic toxicity compared to traditional IV therapies. RenovoRx aims to transform cancer care by enabling safer, more precise delivery of diagnostic and therapeutic agents to patients with high unmet medical needs.Explore more
RenovoRx Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is RenovoRx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on RenovoRx recently announced quarterly report
RenovoRx, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if RenovoRx had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at RenovoRx
Check out if RenovoRx is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once RenovoRx has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when RenovoRx launches new products
Check if RenovoRx has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to RenovoRx
Compare insights from companies similar to RenovoRx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
RenovoRx is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
RenovoRx is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about RenovoRx.
RenovoRx financials insights
Gather financial insights about RenovoRx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series B
$1.1M
2018
Unspecified
$10M
2024
Share Placement
$6.1M
2026
Stock/Share Issuance
$10M
RenovoRx Tech Stack
A closer look at the technologies used by RenovoRx
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Earnings
RenovoRx has reported gross profit of $766,000 for Q2 2026, representing a gross margin of approximately 84%, consistent with the approximately 85% gross margin reported in Q1 2026.
Earnings, Finance
Project
reported that a peer-reviewed case study by researchers at Moffitt Cancer Center, published in Radiology Case Reports in Q2 2026, found that PET-CT imaging showed a meaningful reduction in tumor metabolic activity following TAMP-delivered treatment in locally advanced pancreatic cancer, suggesting PET imaging may help optimize monitoring of therapeutic response.
Medical Research, Radiology
Project
reported that the pharmacokinetics sub-study of the TIGeR-PaC trial has been accepted for publication in the Journal of Cancer Chemotherapy & Pharmacology, with findings supporting TAMP as a targeted delivery method for gemcitabine that may increase local drug potency while reducing systemic exposure and common side effects.
Medical Research
Earnings
Earnings, Finance
RenovoRx News & Media
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical TrialRenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
As Commercial and Clinical Programs Advance, RenovoRx Continues to Strengthen its Global Intellectual Property Portfolio with 20 Issued or Allowed Patents and 13 Pending Patents to Support the Commercialization of RenovoCath As Commercial and Clinical Programs Advance, RenovoRx Continues to Strengthen its Global Intellectual Property Portfolio with 20 Issued or Allowed Patents and 13 Pending Patents to Support the Commercialization of RenovoCathRenovoRx Q2 Earnings Call Highlights
RenovoRx (NASDAQ:RNXT) reported record second-quarter revenue as it expanded its commercial cancer-center network and advanced its clinical program for locally advanced pancreatic cancer. For the quarter ended June 30, 2026, the company generated revenue of $909,000, up approximately 61% from $563,RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
Increases 2026 Annual Revenue Guidance to a Range of $3.75M to $4.25M
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding RenovoRx
Sign Up For FreeTo access detailed company insights
RenovoRx, Inc. (Nasdaq: RNXT) is a targeted oncology company focused on developing and commercializing innovative local drug-delivery therapies for cancer. The companys FDA-cleared RenovoCath® catheter and patented Trans-Arterial Micro-Perfusion (TAMP) platform are designed to deliver therapeutics directly through the arterial wall to bathe tumors... Read More
